The National Cancer Institute (NCI)-Developmental Therapeutics Program (DTP) - Screening Technologies Branch (STB, in collaboration with the NCI-Retroviral Assembly and Protein Chemistry Laboratories and the AIDS Vaccine Program), have identified several classes of lead compounds which are antagonists of high affinity binding of the HIV-1 nucleocapsid-p7 protein to nucleic acids [e.g. alternating d(TG)n], thereby inhibiting viral replication in HIV-1 infected human CEM SS cells. One such example is the substituted arylstibonic acid, compound I which exhibits in vitro activity in a virus disassembly assay, disrupting viral particles formed from in vitro-assembled gag particles. Compound I also exhibits excellent correlation between virus particle disassembly activity and NC-p7 and ^p6- d(TG)4 complex disruption and protects CEM SS cells from cytopathic effects of the HIV-1 virus in whole cell/live virus assays. The NCI-DTP-STB now seeks a CRADA collaborator to participate in the preclinical anti-HIV viral development of compound I which possesses a distinct mechanism of action, is relatively non-toxic and has the potential for use in combination with antiviral drugs acting through differing mechanisms of action.
Patent Status and Pertinent References:
Contact
Information:
John D. Hewes,
Ph.D., Technology Transfer Center, NCI
Phone: 301-435-3121; E-mail: hewesj@mail.nih.gov
Reference: #34
This opportunity is also listed under the following categories:
Methods To Treat Fatty Liver Disease
Transgenic Mouse Model For Development Of Cancer Therapeutics
Therapeutics Based On The Induced Internalization Of Surface Receptors
TTC maintains an e-mail service to notify you of new Collaborative Opportunities. If you would like to receive these emails, please sign up below. If you'd like to unsubscribe you can use this form as well.